The global Imatinib Mesylate API market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Imatinib Mesylate API is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Imatinib Mesylate API is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Imatinib Mesylate API include Aurobindo Pharma Ltd, Formosa Laboratories Inc, Cadila Healthcare Ltd, Laurus Labs Ltd, Msn Laboratories Private Ltd, Intas Pharmaceuticals Ltd, Zydus Lifesciences Ltd, Hetero Labs Ltd and Shilpa Pharma Lifesciences Ltd, etc. in 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Imatinib Mesylate API, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Imatinib Mesylate API.
The Imatinib Mesylate API market size, estimations, and forecasts are provided in terms of sales volume (Tons) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Imatinib Mesylate API market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Imatinib Mesylate API manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Aurobindo Pharma Ltd
Formosa Laboratories Inc
Cadila Healthcare Ltd
Laurus Labs Ltd
Msn Laboratories Private Ltd
Intas Pharmaceuticals Ltd
Zydus Lifesciences Ltd
Hetero Labs Ltd
Shilpa Pharma Lifesciences Ltd
Teva Pharmaceutical Industries Ltd
Cipla Ltd
Acebright India Pharma Private Ltd
Fis Fabbrica Italiana Sintetici Spa
Dr Reddys Laboratories Ltd
Natco Pharma Ltd
Sun Pharmaceutical Industries Ltd
Reliance Life Sciences Pvt Ltd
Zhejiang Jiuzhou Pharmaceutical Co Ltd
Tai Heng Industry Group Co Ltd
Shandong Anxin Pharmaceutical Co Ltd
Segment by Type
±Ê³Ü°ù¾±³Ù²â≥99%
Purity<99%
Segment by Application
Tablet
Capsule
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Imatinib Mesylate API manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Imatinib Mesylate API in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Imatinib Mesylate API Market Overview
1.1 Product Overview and Scope of Imatinib Mesylate API
1.2 Imatinib Mesylate API Segment by Type
1.2.1 Global Imatinib Mesylate API Market Value Comparison by Type (2023-2029)
1.2.2 ±Ê³Ü°ù¾±³Ù²â≥99%
1.2.3 Purity<99%
1.3 Imatinib Mesylate API Segment by Application
1.3.1 Global Imatinib Mesylate API Market Value by Application: (2023-2029)
1.3.2 Tablet
1.3.3 Capsule
1.4 Global Imatinib Mesylate API Market Size Estimates and Forecasts
1.4.1 Global Imatinib Mesylate API Revenue 2018-2029
1.4.2 Global Imatinib Mesylate API Sales 2018-2029
1.4.3 Global Imatinib Mesylate API Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Imatinib Mesylate API Market Competition by Manufacturers
2.1 Global Imatinib Mesylate API Sales Market Share by Manufacturers (2018-2023)
2.2 Global Imatinib Mesylate API Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Imatinib Mesylate API Average Price by Manufacturers (2018-2023)
2.4 Global Imatinib Mesylate API Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Imatinib Mesylate API, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Imatinib Mesylate API, Product Type & Application
2.7 Imatinib Mesylate API Market Competitive Situation and Trends
2.7.1 Imatinib Mesylate API Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Imatinib Mesylate API Players Market Share by Revenue
2.7.3 Global Imatinib Mesylate API Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Imatinib Mesylate API Retrospective Market Scenario by Region
3.1 Global Imatinib Mesylate API Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Imatinib Mesylate API Global Imatinib Mesylate API Sales by Region: 2018-2029
3.2.1 Global Imatinib Mesylate API Sales by Region: 2018-2023
3.2.2 Global Imatinib Mesylate API Sales by Region: 2024-2029
3.3 Global Imatinib Mesylate API Global Imatinib Mesylate API Revenue by Region: 2018-2029
3.3.1 Global Imatinib Mesylate API Revenue by Region: 2018-2023
3.3.2 Global Imatinib Mesylate API Revenue by Region: 2024-2029
3.4 North America Imatinib Mesylate API Market Facts & Figures by Country
3.4.1 North America Imatinib Mesylate API Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Imatinib Mesylate API Sales by Country (2018-2029)
3.4.3 North America Imatinib Mesylate API Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Imatinib Mesylate API Market Facts & Figures by Country
3.5.1 Europe Imatinib Mesylate API Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Imatinib Mesylate API Sales by Country (2018-2029)
3.5.3 Europe Imatinib Mesylate API Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Imatinib Mesylate API Market Facts & Figures by Country
3.6.1 Asia Pacific Imatinib Mesylate API Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Imatinib Mesylate API Sales by Country (2018-2029)
3.6.3 Asia Pacific Imatinib Mesylate API Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Imatinib Mesylate API Market Facts & Figures by Country
3.7.1 Latin America Imatinib Mesylate API Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Imatinib Mesylate API Sales by Country (2018-2029)
3.7.3 Latin America Imatinib Mesylate API Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Imatinib Mesylate API Market Facts & Figures by Country
3.8.1 Middle East and Africa Imatinib Mesylate API Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Imatinib Mesylate API Sales by Country (2018-2029)
3.8.3 Middle East and Africa Imatinib Mesylate API Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Imatinib Mesylate API Sales by Type (2018-2029)
4.1.1 Global Imatinib Mesylate API Sales by Type (2018-2023)
4.1.2 Global Imatinib Mesylate API Sales by Type (2024-2029)
4.1.3 Global Imatinib Mesylate API Sales Market Share by Type (2018-2029)
4.2 Global Imatinib Mesylate API Revenue by Type (2018-2029)
4.2.1 Global Imatinib Mesylate API Revenue by Type (2018-2023)
4.2.2 Global Imatinib Mesylate API Revenue by Type (2024-2029)
4.2.3 Global Imatinib Mesylate API Revenue Market Share by Type (2018-2029)
4.3 Global Imatinib Mesylate API Price by Type (2018-2029)
5 Segment by Application
5.1 Global Imatinib Mesylate API Sales by Application (2018-2029)
5.1.1 Global Imatinib Mesylate API Sales by Application (2018-2023)
5.1.2 Global Imatinib Mesylate API Sales by Application (2024-2029)
5.1.3 Global Imatinib Mesylate API Sales Market Share by Application (2018-2029)
5.2 Global Imatinib Mesylate API Revenue by Application (2018-2029)
5.2.1 Global Imatinib Mesylate API Revenue by Application (2018-2023)
5.2.2 Global Imatinib Mesylate API Revenue by Application (2024-2029)
5.2.3 Global Imatinib Mesylate API Revenue Market Share by Application (2018-2029)
5.3 Global Imatinib Mesylate API Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Aurobindo Pharma Ltd
6.1.1 Aurobindo Pharma Ltd Corporation Information
6.1.2 Aurobindo Pharma Ltd Description and Business Overview
6.1.3 Aurobindo Pharma Ltd Imatinib Mesylate API Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Aurobindo Pharma Ltd Imatinib Mesylate API Product Portfolio
6.1.5 Aurobindo Pharma Ltd Recent Developments/Updates
6.2 Formosa Laboratories Inc
6.2.1 Formosa Laboratories Inc Corporation Information
6.2.2 Formosa Laboratories Inc Description and Business Overview
6.2.3 Formosa Laboratories Inc Imatinib Mesylate API Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Formosa Laboratories Inc Imatinib Mesylate API Product Portfolio
6.2.5 Formosa Laboratories Inc Recent Developments/Updates
6.3 Cadila Healthcare Ltd
6.3.1 Cadila Healthcare Ltd Corporation Information
6.3.2 Cadila Healthcare Ltd Description and Business Overview
6.3.3 Cadila Healthcare Ltd Imatinib Mesylate API Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Cadila Healthcare Ltd Imatinib Mesylate API Product Portfolio
6.3.5 Cadila Healthcare Ltd Recent Developments/Updates
6.4 Laurus Labs Ltd
6.4.1 Laurus Labs Ltd Corporation Information
6.4.2 Laurus Labs Ltd Description and Business Overview
6.4.3 Laurus Labs Ltd Imatinib Mesylate API Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Laurus Labs Ltd Imatinib Mesylate API Product Portfolio
6.4.5 Laurus Labs Ltd Recent Developments/Updates
6.5 Msn Laboratories Private Ltd
6.5.1 Msn Laboratories Private Ltd Corporation Information
6.5.2 Msn Laboratories Private Ltd Description and Business Overview
6.5.3 Msn Laboratories Private Ltd Imatinib Mesylate API Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Msn Laboratories Private Ltd Imatinib Mesylate API Product Portfolio
6.5.5 Msn Laboratories Private Ltd Recent Developments/Updates
6.6 Intas Pharmaceuticals Ltd
6.6.1 Intas Pharmaceuticals Ltd Corporation Information
6.6.2 Intas Pharmaceuticals Ltd Description and Business Overview
6.6.3 Intas Pharmaceuticals Ltd Imatinib Mesylate API Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Intas Pharmaceuticals Ltd Imatinib Mesylate API Product Portfolio
6.6.5 Intas Pharmaceuticals Ltd Recent Developments/Updates
6.7 Zydus Lifesciences Ltd
6.6.1 Zydus Lifesciences Ltd Corporation Information
6.6.2 Zydus Lifesciences Ltd Description and Business Overview
6.6.3 Zydus Lifesciences Ltd Imatinib Mesylate API Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Zydus Lifesciences Ltd Imatinib Mesylate API Product Portfolio
6.7.5 Zydus Lifesciences Ltd Recent Developments/Updates
6.8 Hetero Labs Ltd
6.8.1 Hetero Labs Ltd Corporation Information
6.8.2 Hetero Labs Ltd Description and Business Overview
6.8.3 Hetero Labs Ltd Imatinib Mesylate API Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Hetero Labs Ltd Imatinib Mesylate API Product Portfolio
6.8.5 Hetero Labs Ltd Recent Developments/Updates
6.9 Shilpa Pharma Lifesciences Ltd
6.9.1 Shilpa Pharma Lifesciences Ltd Corporation Information
6.9.2 Shilpa Pharma Lifesciences Ltd Description and Business Overview
6.9.3 Shilpa Pharma Lifesciences Ltd Imatinib Mesylate API Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Shilpa Pharma Lifesciences Ltd Imatinib Mesylate API Product Portfolio
6.9.5 Shilpa Pharma Lifesciences Ltd Recent Developments/Updates
6.10 Teva Pharmaceutical Industries Ltd
6.10.1 Teva Pharmaceutical Industries Ltd Corporation Information
6.10.2 Teva Pharmaceutical Industries Ltd Description and Business Overview
6.10.3 Teva Pharmaceutical Industries Ltd Imatinib Mesylate API Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Teva Pharmaceutical Industries Ltd Imatinib Mesylate API Product Portfolio
6.10.5 Teva Pharmaceutical Industries Ltd Recent Developments/Updates
6.11 Cipla Ltd
6.11.1 Cipla Ltd Corporation Information
6.11.2 Cipla Ltd Imatinib Mesylate API Description and Business Overview
6.11.3 Cipla Ltd Imatinib Mesylate API Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Cipla Ltd Imatinib Mesylate API Product Portfolio
6.11.5 Cipla Ltd Recent Developments/Updates
6.12 Acebright India Pharma Private Ltd
6.12.1 Acebright India Pharma Private Ltd Corporation Information
6.12.2 Acebright India Pharma Private Ltd Imatinib Mesylate API Description and Business Overview
6.12.3 Acebright India Pharma Private Ltd Imatinib Mesylate API Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Acebright India Pharma Private Ltd Imatinib Mesylate API Product Portfolio
6.12.5 Acebright India Pharma Private Ltd Recent Developments/Updates
6.13 Fis Fabbrica Italiana Sintetici Spa
6.13.1 Fis Fabbrica Italiana Sintetici Spa Corporation Information
6.13.2 Fis Fabbrica Italiana Sintetici Spa Imatinib Mesylate API Description and Business Overview
6.13.3 Fis Fabbrica Italiana Sintetici Spa Imatinib Mesylate API Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Fis Fabbrica Italiana Sintetici Spa Imatinib Mesylate API Product Portfolio
6.13.5 Fis Fabbrica Italiana Sintetici Spa Recent Developments/Updates
6.14 Dr Reddys Laboratories Ltd
6.14.1 Dr Reddys Laboratories Ltd Corporation Information
6.14.2 Dr Reddys Laboratories Ltd Imatinib Mesylate API Description and Business Overview
6.14.3 Dr Reddys Laboratories Ltd Imatinib Mesylate API Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Dr Reddys Laboratories Ltd Imatinib Mesylate API Product Portfolio
6.14.5 Dr Reddys Laboratories Ltd Recent Developments/Updates
6.15 Natco Pharma Ltd
6.15.1 Natco Pharma Ltd Corporation Information
6.15.2 Natco Pharma Ltd Imatinib Mesylate API Description and Business Overview
6.15.3 Natco Pharma Ltd Imatinib Mesylate API Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Natco Pharma Ltd Imatinib Mesylate API Product Portfolio
6.15.5 Natco Pharma Ltd Recent Developments/Updates
6.16 Sun Pharmaceutical Industries Ltd
6.16.1 Sun Pharmaceutical Industries Ltd Corporation Information
6.16.2 Sun Pharmaceutical Industries Ltd Imatinib Mesylate API Description and Business Overview
6.16.3 Sun Pharmaceutical Industries Ltd Imatinib Mesylate API Sales, Revenue and Gross Margin (2018-2023)
6.16.4 Sun Pharmaceutical Industries Ltd Imatinib Mesylate API Product Portfolio
6.16.5 Sun Pharmaceutical Industries Ltd Recent Developments/Updates
6.17 Reliance Life Sciences Pvt Ltd
6.17.1 Reliance Life Sciences Pvt Ltd Corporation Information
6.17.2 Reliance Life Sciences Pvt Ltd Imatinib Mesylate API Description and Business Overview
6.17.3 Reliance Life Sciences Pvt Ltd Imatinib Mesylate API Sales, Revenue and Gross Margin (2018-2023)
6.17.4 Reliance Life Sciences Pvt Ltd Imatinib Mesylate API Product Portfolio
6.17.5 Reliance Life Sciences Pvt Ltd Recent Developments/Updates
6.18 Zhejiang Jiuzhou Pharmaceutical Co Ltd
6.18.1 Zhejiang Jiuzhou Pharmaceutical Co Ltd Corporation Information
6.18.2 Zhejiang Jiuzhou Pharmaceutical Co Ltd Imatinib Mesylate API Description and Business Overview
6.18.3 Zhejiang Jiuzhou Pharmaceutical Co Ltd Imatinib Mesylate API Sales, Revenue and Gross Margin (2018-2023)
6.18.4 Zhejiang Jiuzhou Pharmaceutical Co Ltd Imatinib Mesylate API Product Portfolio
6.18.5 Zhejiang Jiuzhou Pharmaceutical Co Ltd Recent Developments/Updates
6.19 Tai Heng Industry Group Co Ltd
6.19.1 Tai Heng Industry Group Co Ltd Corporation Information
6.19.2 Tai Heng Industry Group Co Ltd Imatinib Mesylate API Description and Business Overview
6.19.3 Tai Heng Industry Group Co Ltd Imatinib Mesylate API Sales, Revenue and Gross Margin (2018-2023)
6.19.4 Tai Heng Industry Group Co Ltd Imatinib Mesylate API Product Portfolio
6.19.5 Tai Heng Industry Group Co Ltd Recent Developments/Updates
6.20 Shandong Anxin Pharmaceutical Co Ltd
6.20.1 Shandong Anxin Pharmaceutical Co Ltd Corporation Information
6.20.2 Shandong Anxin Pharmaceutical Co Ltd Imatinib Mesylate API Description and Business Overview
6.20.3 Shandong Anxin Pharmaceutical Co Ltd Imatinib Mesylate API Sales, Revenue and Gross Margin (2018-2023)
6.20.4 Shandong Anxin Pharmaceutical Co Ltd Imatinib Mesylate API Product Portfolio
6.20.5 Shandong Anxin Pharmaceutical Co Ltd Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Imatinib Mesylate API Industry Chain Analysis
7.2 Imatinib Mesylate API Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Imatinib Mesylate API Production Mode & Process
7.4 Imatinib Mesylate API Sales and Marketing
7.4.1 Imatinib Mesylate API Sales Channels
7.4.2 Imatinib Mesylate API Distributors
7.5 Imatinib Mesylate API Customers
8 Imatinib Mesylate API Market Dynamics
8.1 Imatinib Mesylate API Industry Trends
8.2 Imatinib Mesylate API Market Drivers
8.3 Imatinib Mesylate API Market Challenges
8.4 Imatinib Mesylate API Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Aurobindo Pharma Ltd
Formosa Laboratories Inc
Cadila Healthcare Ltd
Laurus Labs Ltd
Msn Laboratories Private Ltd
Intas Pharmaceuticals Ltd
Zydus Lifesciences Ltd
Hetero Labs Ltd
Shilpa Pharma Lifesciences Ltd
Teva Pharmaceutical Industries Ltd
Cipla Ltd
Acebright India Pharma Private Ltd
Fis Fabbrica Italiana Sintetici Spa
Dr Reddys Laboratories Ltd
Natco Pharma Ltd
Sun Pharmaceutical Industries Ltd
Reliance Life Sciences Pvt Ltd
Zhejiang Jiuzhou Pharmaceutical Co Ltd
Tai Heng Industry Group Co Ltd
Shandong Anxin Pharmaceutical Co Ltd
Ìý
Ìý
*If Applicable.
